Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: Case report and literature review

Endocrine Practice

Volumn 16, Issue 5, 2010, Pages 851-854

  Mansoori, Lela S ^a   Catel, Colin P ^a   Rothman, Micol S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; NARCOTIC AGENT; OSTEOCALCIN; PAMIDRONIC ACID; SUMATRIPTAN; ZOLEDRONIC ACID;

ADULT; ALBRIGHT SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE LESION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTRAST ENHANCEMENT; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HEADACHE; HUMAN; MALE; OCCIPITAL BONE; OSTEOSCLEROSIS; PATIENT MONITORING; POSTERIOR FOSSA; SKULL; TREATMENT OUTCOME;

EID: 78149337397     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10136.CR     Document Type: Article

References (17)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325:1688-1695.
2. McCune DJ. Osteitis fibrosa cystica: The case of a nine year old girl who also exhibits precocious puberty, multiple pigmentations of the skin and hyperthyroidism. Am J Dis Child. 1936;52:743-744.
3. Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22:55-69.
4. Riminucci M, Liu B, Corsi A, et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks. J Pathol. 1999;187:249-258.
5. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Longterm effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997;12:1746-1752.
6. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343:953-954.
7. Weinstein RS. Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density. J Bone Miner Res. 1997;12:1314-1315.
8. Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 2001;382:6-12.
9. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88:4569-4575.
10. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. J Pediatr. 2000;137:403-409.
11. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21(Suppl 2): P114-P119.
12. Mäkitie AA, Törnwall J, Mäkitie O. Bisphosphonate treatment in craniofacial fibrous dysplasia-a case report and review of the literature. Clin Rheumatol. 2008;27:809-812.
13. Kos M, Luczak K, Godzinski J, Klempous J. Treatment of monostotic fibrous dysplasia with pamidronate. J Craniomaxillofac Surg. 2004;32:10-15.
14. Levy ML, Chen TC, Weiss MH. Monostotic fibrous dysplasia of the clivus. Case report. J Neurosurg. 1991;75:800-803.
15. Sato K, Kubota T, Kaneko M, Kawano H, Kobayashi H. Fibrous dysplasia of the clivus. Surg Neurol. 1993;40:522-525.
16. Adada B, Al-Mefty O. Fibrous dysplasia of the clivus. Neurosurgery. 2003;52:318-323.
17. Chao K, Katznelson L. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull. J Neurosurg. 2008;109:889-892.